MSLN and cancer: Recently, we have reported initial work to engineer the Fn3alternativescaffold as a theranostic molecule for MSLN-positive tumors, usingdirected evolution with yeast-surface display., We previously demonstrated that our early generations of engineeredFn3 molecules bound specifically to MSLN-positive cell lines, wereinternalized, and made MSLN-positive cancer cell lines more sensitiveto traditional chemotherapy.